Ignite Creation Date:
2024-05-05 @ 4:49 PM
Last Modification Date:
2024-10-26 @ 9:24 AM
Study NCT ID:
NCT00325065
Status:
COMPLETED
Last Update Posted:
2017-07-02
First Post:
2006-05-11
Brief Title:
Identifying the Role of Oxytocin and Vasopressin in the Functioning of Neurocognitive Systems Involved in Mood Disorders
Sponsor:
National Institute of Mental Health NIMH
Organization:
National Institutes of Health Clinical Center CC
Study Overview
Official Title:
Identifying the Role of Oxytocin and Vasopressin in the Functioning of Neurocognitive Systems Involved in Mood Disorders
Status:
COMPLETED
Status Verified Date:
2010-04-16
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The goal of this protocol broadly stated is to use targeted manipulations with intranasally administered oxytocin OT and arginine vasopressin AVP in conjunction with neurocognitive and neuroimaging paradigms to evaluate claims that OT and AVP inhibit and facilitate respectively the effective processing of aversive signals Moreover we wish to examine whether increased vasopressin levels will increase and increased oxytocin levels decrease the neural response in the amygdala and other limbic structures to aversive stimuli In addition we wish to assess whether OT and AVP administration will lead to the facilitation of conspecific recognition as appears to be the case for other mammalian species
Detailed Description:
Objective
The goal of this protocol broadly stated is to use targeted manipulations with intranasally administered oxytocin OT and arginine vasopressin AVP in conjunction with neurocognitive and neuroimaging paradigms to evaluate claims that OT and AVP inhibit and facilitate respectively the effective processing of aversive signals
Study Population
A total of 216 healthy male and female adults between 20-40 years of age
Design
This protocol will involve a series of independent studies Each study will require one visit in addition to a screening visit involves a physical and psychiatric assessment The study visit itself will involve pharmacological challenge followed by neurocognitive or neuroimaging testing
Outcome Measures
Moreover we wish to examine whether increased vasopressin levels will increase and increased oxytocin levels decrease the neural response in the amygdala and other limbic structures to aversive stimuli In addition we wish to assess whether OT and AVP administration will lead to the facilitation of conspecific recognition as appears to be the case for other mammalian species
The goal of this protocol broadly stated is to use targeted manipulations with intranasally administered oxytocin OT and arginine vasopressin AVP in conjunction with neurocognitive and neuroimaging paradigms to evaluate claims that OT and AVP inhibit and facilitate respectively the effective processing of aversive signals
Study Population
A total of 216 healthy male and female adults between 20-40 years of age
Design
This protocol will involve a series of independent studies Each study will require one visit in addition to a screening visit involves a physical and psychiatric assessment The study visit itself will involve pharmacological challenge followed by neurocognitive or neuroimaging testing
Outcome Measures
Moreover we wish to examine whether increased vasopressin levels will increase and increased oxytocin levels decrease the neural response in the amygdala and other limbic structures to aversive stimuli In addition we wish to assess whether OT and AVP administration will lead to the facilitation of conspecific recognition as appears to be the case for other mammalian species
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 06-M-0155 | None | None | None |